• Explore /
  • Poster
  • / A phase 1/2 study to evaluate safety and efficacy of nivolumab plus brentuximab vedotin in patients with CD30-expressing relapsed/refractory non-Hodgkin lymphomas (NHLs).

A phase 1/2 study to evaluate safety and efficacy of nivolumab plus brentuximab vedotin in patients with CD30-expressing relapsed/refractory non-Hodgkin lymphomas (NHLs).

Abstract Poster

Authors

null

Philippe Armand

Dana-Farber Cancer Institute, Boston, MA

Philippe Armand , Joshua Brody , Paul M. Barr , Andrei R. Shustov , Alison J. Moskowitz , Justin Paul Kline , Kerry J. Savage , John Kuruvilla , Neil C. Josephson , Pier Luigi Zinzani , Gilles A. Salles , Aisha Masood , Stephen Maxted Ansell

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT02581631

Citation

J Clin Oncol 34, 2016 (suppl; abstr TPS7576)

DOI

10.1200/JCO.2016.34.15_suppl.TPS7576

Abstract #

TPS7576

Poster Bd #

130a

Abstract Disclosures

Similar Posters

First Author: Paolo Antonio Ascierto

First Author: Guillermo Garcia-Manero

First Author: Guillermo De Velasco

First Author: Bruno Sangro